Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction

Prospects of application of inhibitors of PD-1/PD-L1 checkpoints in malignant tumors of the stomach and esophagogastric junction

Malignant tumors of the stomach and esophagogastric junction in advanced stages progress quite aggressively, and the prospects for treatment of these patients remain unpromising. The use of checkpoint-inhibitors has proven to be an advanced treatment method for various types of cancer around the wor...

Full description

Bibliographic Details
Main Authors:	D. D. Sakaeva, A. A. Melnikova
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2020-12-01
Series:	Медицинский совет
Subjects:	nivolumab ipilimumab pembrolizumab regorafenib immunotherapy checkpoint inhibitors microsatellite instability
Online Access:	https://www.med-sovet.pro/jour/article/view/5929

Similar Items

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
by: Chiao-En Wu, et al.
Published: (2020-06-01)

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies
by: Marc-Oliver Grimm, et al.
Published: (2020-02-01)

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
by: Houssein Safa, et al.
Published: (2019-11-01)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by: Carl Morrison, et al.
Published: (2018-05-01)

Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma
by: Natasha Lakin, et al.
Published: (2017-07-01)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
by: Hisato Kawakami, et al.
Published: (2021-02-01)

Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital
by: Ricardo Fernández-Ferreira, et al.
Published: (2019-12-01)

Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma
by: Jan-Michael Werner, et al.
Published: (2019-02-01)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01)

Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by: Jeffrey M. Conroy, et al.
Published: (2019-01-01)

Associated Myocarditis: A Predictive Factor for Response?
by: Walid Shalata, et al.
Published: (2020-05-01)

Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
by: Giuseppe Fanciulli, et al.
Published: (2021-06-01)

CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01)

Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
by: Nabil E. Omar, et al.
Published: (2020-10-01)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
by: Matthew D Biniakewitz, et al.
Published: (2021-01-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Jiang Y, et al.
Published: (2019-02-01)

Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
by: Ulrich Sterz, et al.
Published: (2021-08-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
by: Ernesto Rossi, et al.
Published: (2019-07-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
by: Nicoletta F. Jaberg-Bentele, et al.
Published: (2017-03-01)

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-04-01)

Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
by: Katrin Goepfert, et al.
Published: (2019-05-01)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
by: Seetharamu N, et al.
Published: (2017-07-01)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
by: Bal, W., et al.
Published: (2022)

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
by: Dmitrii Shek, et al.
Published: (2021-08-01)

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
by: Roy Herbst, et al.
Published: (2021-07-01)

Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
by: Shifaa M. Abdin, et al.
Published: (2018-01-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines
by: Saralinh Trinh, et al.
Published: (2019-01-01)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
by: Pawel Teterycz, et al.
Published: (2020-10-01)

Immunotherapy in Small Cell Lung Cancer
by: Giovanna Esposito, et al.
Published: (2020-09-01)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
by: Hsiao-Ling Chen, et al.
Published: (2020-12-01)